Compare TENX & NSRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TENX | NSRX |
|---|---|---|
| Founded | 1967 | 2019 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.2M | 52.5M |
| IPO Year | N/A | 2025 |
| Metric | TENX | NSRX |
|---|---|---|
| Price | $12.82 | $5.60 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 2 |
| Target Price | ★ $22.50 | $20.50 |
| AVG Volume (30 Days) | ★ 294.1K | 4.6K |
| Earning Date | 03-24-2026 | 03-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.63 | $4.90 |
| 52 Week High | $18.38 | $9.99 |
| Indicator | TENX | NSRX |
|---|---|---|
| Relative Strength Index (RSI) | 46.69 | 41.46 |
| Support Level | $12.53 | $4.90 |
| Resistance Level | $14.08 | $6.30 |
| Average True Range (ATR) | 0.95 | 0.41 |
| MACD | -0.23 | -0.04 |
| Stochastic Oscillator | 17.74 | 40.49 |
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
Nasus Pharma Ltd is a clinical-stage specialty pharmaceutical company focused principally on the development of intranasal drugs to treat emergency medical conditions. It is engaged in developing a number of intranasal powder products based on its a microsphere technology, aimed at assisting patients in several acute emergency situations such as opioid overdose and anaphylactic shock. Its portfolio comprises a number of programs: Intranasal Naloxone completed pivotal study and Intranasal Epinephrine (phase 2) as well as a number of preclinical POC programs.